Provided by Tiger Trade Technology Pte. Ltd.

OPKO Health

1.24
+0.01000.81%
Post-market: 1.250.0100+0.81%19:41 EST
Volume:3.38M
Turnover:4.20M
Market Cap:951.95M
PE:-5.01
High:1.25
Open:1.24
Low:1.23
Close:1.23
52wk High:2.04
52wk Low:1.11
Shares:767.70M
Float Shares:351.00M
Volume Ratio:0.83
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2475
EPS(LYR):-0.0767
ROE:-13.32%
ROA:-6.15%
PB:0.73
PE(LYR):-16.17

Loading ...

BRIEF-Opko Health And Entera Bio Expand Partnership To Advance First-In-Class Oral Long Acting Pth Tablet For Patients With Hypoparathyroidism

Reuters
·
Feb 04

OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting Pth Tablet for Patients With Hypoparathyroidism

THOMSON REUTERS
·
Feb 04

Steve Rubin Joins Entera Bio Board as Gerry Ostrov Steps Down

Reuters
·
Feb 04

OPKO Health, Inc. (NASDAQ:OPK) insiders have recently purchased stock and their bets paid off last week as company hit US$1.0b market cap

Simply Wall St.
·
Jan 08

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Dec 12, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Nov 25, 2025

OPKO Health Initiated at Neutral by JP Morgan

Dow Jones
·
Nov 20, 2025

Does CEO Frost’s Share Purchase Offset Concerns About OPKO Health’s (OPK) Sales Outlook?

Simply Wall St.
·
Nov 20, 2025

U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's

Reuters
·
Nov 20, 2025

OPKO Health Inc : JP Morgan Initiates Coverage With Neutral Rating

THOMSON REUTERS
·
Nov 20, 2025

OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire
·
Nov 20, 2025

Opko Health CEO Phillip Frost Reports Acquisition of Common Shares

Reuters
·
Nov 19, 2025

Entera Bio reports Q3 net loss of $3.2 million

Reuters
·
Nov 15, 2025

Press Release: NextPlat Reports Third Quarter 2025 Results

Dow Jones
·
Nov 13, 2025

OPKO Health (OPK): Evaluating Valuation After Oncology Business Sale and Updated Earnings Guidance

Simply Wall St.
·
Nov 12, 2025

Is OPKO Health's Post-Oncology Revenue Guidance Reset Shifting the Investment Case for OPK?

Simply Wall St.
·
Nov 10, 2025

OPKO Health (OPK) Is Down 9.3% After Regeneron Collaboration and Asset Sale Announcement – Has the Bull Case Changed?

Simply Wall St.
·
Nov 01, 2025

Opko Health CEO and Chairman Phillip Frost Reports Acquisition of Common Shares

Reuters
·
Nov 01, 2025

OPKO Health Shares Fall After Jefferies Downgrade

MT Newswires Live
·
Nov 01, 2025

Stock Track | OPKO Health Plummets 5.14% Following Jefferies Downgrade and Price Target Cut

Stock Track
·
Nov 01, 2025